On Jun. 21, 2021, Cumberland Pharma released a series of case reports describing the effectiveness of Vibativ (telavancin) in treating secondary bacterial infections in COVID-19 patients ﾖ particularly those with other significant health problems, such as obesity, diabetes and heart disease.

The dossier of patient case studies outlined five real-world instances where Vibativ effectively and safely treated hospital-acquired and ventilator-associated bacterial pneumonia in COVID-19 patients.